

Restructuring Advisory – Molecular Insight Pharmaceuticals, Inc.



PIONEERS IN MEDICINE. PARTNERS IN CARE.

\$215,000,000

Restructuring Advisory

May 2011

*The undersigned acted as
financial advisor to the Company*



Highlights

- Molecular Insight Pharmaceuticals, Inc. (“MIPI” or the “Company”) engaged M.M. Dillon & Co. (“Dillon”) to act as its exclusive financial advisor with respect to a financial restructuring of its outstanding debt obligations.
- Dillon performed a comprehensive assessment and review of MIPI’s business operations and financial situation and negotiated a full debt for equity exchange and the infusion of additional capital for the Company.
- In May, 2011, MIPI successfully confirmed a Plan of Reorganization and restructured aggregate liabilities of approximately \$215,000,000 while also raising \$40,000,000 of exit financing.

The Company

Molecular Insight Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals for use in oncology.

The Company has five clinical-stage candidates in development. Azedra and Onalta are being developed for the treatment of neuroendocrine cancers; Trofex is being developed for the detection of metastatic prostate cancer; and Solazed is being developed for the treatment of metastatic melanoma. The only non-oncology product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia (insufficient blood flow to the heart muscle).

Contact Us

Michiel McCarty

Head of Investment Banking

mmccarty@mmdillon.com

(203) 569 - 6823

About M.M. Dillon & Co. (Formerly CRT Investment Banking LLC)

M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee-owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years experience with major Wall Street firms.